Author:
Alibolandi Mona,Abnous Khalil,Mohammadi Marzieh,Hadizadeh Farzin,Sadeghi Fatemeh,Taghavi Sahar,Jaafari Mahmoud Reza,Ramezani Mohammad
Funder
Mashhad University of Medical Sciences
Reference41 articles.
1. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes;Tahover;Anti-Cancer Drugs,2015
2. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis;Rafiyath;Exp. Hematol. Oncol.,2012
3. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil-mimic®, Caelyx®, DOXOrubicin, and SinaDoxosome;Wibroe;J. Control. Release,2016
4. Doxil-mimic®—the first FDA-approved nano-drug: lessons learned;Barenholz;J. Control. Release,2012
5. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model;Moosava;Colloids Surf. B: Biointerfaces,2016
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献